Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.90 |
| ▸ | NCF1 | P14598 | 7/20 | 0.67 |
| ▸ | HTR6 | P50406 | 3/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
| ▸ | AXL | P30530 | 1/20 | 0.65 |
| ▸ | HRH1 | P35367 | 1/20 | 0.65 |
| ▸ | HTR2B | P41595 | 1/20 | 0.65 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.65 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30058924 | 0.95 | ADRB2 (1.00) | ADRB2NCF1HTR6ADRA2AHTR2C | |
| SCHEMBL2711296 | 0.95 | ADRB2 (1.00) | ADRB2NCF1HTR6ADRA2AHTR2C | |
| SCHEMBL15673602 | 0.81 | NCF1 (0.72) | ADRB2NCF1HTR6HTR2BADRB1 | |
| SCHEMBL6595059 | 0.80 | ADRB2 (0.73) | ADRB2NCF1HTR6ADRA2AHTR2C | |
| SCHEMBL2709564 | 0.80 | ADRB2 (0.75) | ADRB2NCF1HTR6ADRA2AHTR2C | |
| SCHEMBL6125222 | 0.79 | ADRB2 (0.72) | ADRB2NCF1HTR6ADRA2AHTR2C | |
| SCHEMBL425929 | 0.79 | ADRB2 (0.71) | ADRB2NCF1HTR6ADRA2AHTR2C | |
| SCHEMBL2708517 | 0.79 | ADRB2 (0.73) | ADRB2NCF1HTR6ADRA2AHTR2C | |
| SCHEMBL2244546 | 0.79 | ADRB2 (1.00) | ADRB2NCF1HTR6ADRA2AHTR2C | |
| SCHEMBL23362148 | 0.77 | ADRB2 (0.68) | ADRB2NCF1HTR6ADRA2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | ADRB2 1530/4885NCF1 4367/4885HTR6 1369/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | ADRB2 1530/4885NCF1 4367/4885HTR6 1369/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | ADRB2 1960/4885NCF1 3736/4885HTR6 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.